Relay Therapeutics (RLAY) Other Operating Expenses (2021 - 2024)

Relay Therapeutics (RLAY) has 4 years of Other Operating Expenses data on file, last reported at -$11.4 million in Q2 2024.

• Other Operating Expenses for Q2 2024 came in at -$11.4 million, down 428.53% year-over-year; the trailing twelve-month figure through Mar 2025 was -$11.4 million (down 56.86% YoY), and the FY2024 annual result was -$13.2 million, down 105.64% from the prior year.
• Other Operating Expenses declined to -$11.4 million in Q2 2024 per RLAY's latest filing, from -$1.8 million in the prior quarter.
• Over five years, Other Operating Expenses peaked at $134.9 million in Q2 2021 and troughed at -$11.4 million in Q2 2024.
• A 4-year average of $8.2 million and a median of -$1.2 million in 2023 frame the typical range for Other Operating Expenses.
• The sharpest annual moves came in 2022 and 2023: Other Operating Expenses tumbled 1361.24% in 2022, then jumped 80.4% in 2023.
• A 4-year view of Other Operating Expenses shows it stood at $836000.0 in 2021, then plunged by 1361.24% to -$10.5 million in 2022, then jumped by 80.4% to -$2.1 million in 2023, then slumped by 450.27% to -$11.4 million in 2024.
• Business Quant data shows RLAY's Other Operating Expenses at -$11.4 million in Q2 2024, -$1.8 million in Q1 2024, and -$2.1 million in Q4 2023.